Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Chimagen Biosciences

Tracked across 1 events · 8 articles · First seen Sep 15, 2026 · Last active Sep 15, 2026

Sentiment
40
Attention
2
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 40
Business
GSK plc announced on September 15, 2026 that it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) for multiple myeloma from privately held clinical-stage biotechnology firm Chimagen Biosciences. The agreement…
Impact: Chimagen Biosciences is the privately held seller of the trispecific TCE, receiving an upfront payment plus up to $750 million in milestone payments and gaining GSK's global development and commercial capabilities for its programme. The agreement also deepens its existing relationship with GSK following the earlier CMG1A46 deal.
Sep 15, 2026 · 8 articles
ERGEN INTELLIGENCE
Track Chimagen Biosciences live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.